A
Alcista
Alcista · 25%ENTA
$6.29
Precio del escenario
$12.000
+0.371 (+3.09%)Al cierre
Loading chart…
- Máximo
- 12.060
- Apertura
- 11.730
- Precio medio ponderado por volumen
- 11.90
- Volumen
- 440.62K
- Capitalización
- 268.34M
- Mínimo
- 11.650
- Importe
- 5.24M
- EV/EBITDA, TTM
- -5.05
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.
Análisis de IA of Enanta Pharmaceuticals Inc (ENTA)
MantenerEnanta Pharmaceuticals is currently trading at $11.64, with a forward P/E ratio of 44.05, indicating that the stock may be overvalued based on future earnings expectations. The RSI is at 49.01, suggesting that the stock is neither overbought nor oversold, which means it may not be the best time to buy. The recent insider buying trend has increased by 137.44%, indicating some confidence from insiders, but the overall financial performance shows significant losses, with a net income loss of $19.5 million in the latest quarter. The main risk is the high forward P/E ratio, which suggests that the stock price may not be justified by future earnings potential, making it a hold for now.
Recomendaciones de analistas (4)
+54.17% de potencial alcista
Comprar
3 Comprar
1 Mantener
0 Vender
Actual: 12.00
Mínimo
17.00
Promedio
18.50
Máximo
20.00
JPMorgan
Sobreponderar
$17
2025-11-14
JPMorgan
2025-11-14
Precio objetivo
$17
Sobreponderar
Jefferies
Comprar
$20
2025-10-01
Jefferies
2025-10-01
Precio objetivo
$20
Comprar
WestPark Capital
Comprar
$24
2025-09-02
WestPark Capital
2025-09-02
Precio objetivo
$24
Comprar
Citizens JMP
Superar al mercado
$25
2025-08-12
Citizens JMP
2025-08-12
Precio objetivo
$25
Superar al mercado
Citizens JMP
Superar al mercado
$24
2025-06-03
Citizens JMP
2025-06-03
Precio objetivo
$24
Superar al mercado
Métricas de valoración
El PER previsto actual de Enanta Pharmaceuticals Inc (ENTA) es 44.05, frente a su media de 5 años de 8.07.
Escenarios de precio de Alphio AI para ENTA
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con ENTA en cartera
Cronología de eventos
Noticias
9.010-26NewsfilterEnanta Pharmaceuticals Launches RSV Clinical Trial for Zelicapavir
7.006-23seekingalphaFederal Court Rules in Favor of Pfizer in Patent Dispute with Enanta
9.006-23seekingalphaAbbVie and Enanta Gain EU Approval for Maviret Label Expansion
- 8.506-23Newsfilter
MAVIRET® Receives EU Approval for Acute HCV Treatment
- 9.006-18Newsfilter
Enanta Pharmaceuticals Advances Zelicapavir Clinical Trials for RSV
Preguntas frecuentes sobre ENTA, respondidas por Alphio AI
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Enanta Pharmaceuticals is currently trading at $11.64, with a forward P/E ratio of 44.05, indicating that the stock may be overvalued based on future earnings expectations. The RSI is at 49.01, suggesting that the stock is neither overbought nor oversold, which means it may not be the best time to buy. The recent insider buying trend has increased by 137.44%, indicating some confidence from insiders, but the overall financial performance shows significant losses, with a net income loss of $19.5 million in the latest quarter. The main risk is the high forward P/E ratio, which suggests that the stock price may not be justified by future earnings potential, making it a hold for now.
4 analysts cover ENTA: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 18.50.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.